LumiraDx Limited (LMDX)

NASDAQ: LMDX · IEX Real-Time Price · USD
9.48 -0.25 (-2.57%)
Jan 25, 2022 4:00 PM EST - Market closed
Market Cap2.40B
Revenue (ttm)234.31M
Net Income (ttm)-93.88M
Shares Out252.70M
EPS (ttm)-2.22
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,904
Open9.59
Previous Close9.73
Day's Range9.29 - 9.60
52-Week Range7.15 - 11.09
Betan/a
AnalystsStrong Buy
Price Target15.06 (+58.9%)
Earnings Daten/a

About LMDX

LumiraDx Limited operates as a point of care diagnostic company. It focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. The company was formerly known as Point of Care Testing Limited and changed its name to LumiraDx Ltd in January 2018. LumiraDx Limited was incorporated in 2002 and is based in London, the United Kingdom.

IndustryDiagnostics & Research
IPO DateJan 26, 2021
Employees1,500
Stock ExchangeNASDAQ
Ticker SymbolLMDX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for LumiraDx stock is "Strong Buy." The 12-month stock price forecast is 15.06, which is an increase of 58.86% from the latest price.

Price Target
$15.06
(58.86% upside)
Analyst Consensus: Strong Buy

News

Wall Street Analysts Believe LumiraDx Limited (LMDX) Could Rally 54%: Here's is How to Trade

The mean of analysts' price targets for LumiraDx Limited (LMDX) points to a 53.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a...

12 hours ago - Zacks Investment Research

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant

LONDON, Jan. 14, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing testing and monitoring of COVID-19 variants ...

1 week ago - PRNewsWire

LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test

LONDON, Jan. 11, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of 2021 as well as expected...

2 weeks ago - PRNewsWire

LumiraDx CRP Test Achieves CE Marking

LONDON, Jan. 11, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its C-reactive protein (CRP) Test has achieved CE Marking. The LumiraD...

2 weeks ago - PRNewsWire

LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking

LONDON, Dec. 23, 2021 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its SARS-CoV-2 & Flu A/B Antigen Test has achieved CE Marking. The mic...

1 month ago - PRNewsWire

LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA ST...

LONDON, Dec. 15, 2021 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX) today announced a partnership with digital health non-profit Audere, to offer a self-collected COVID-19 nasal specimen collection kit that h...

1 month ago - PRNewsWire

Audere Receives FDA Emergency Use Authorization for HealthPulse@home COVID-19 Specimen Collection Test Kit

SEATTLE--(BUSINESS WIRE)-- #covid19--Audere, a digital health nonprofit developing solutions to improve global health, announced that it has received an Emergency Use Authorization (EUA) for HealthPulse...

1 month ago - Business Wire

FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throu...

LONDON, Dec. 1, 2021 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX) announced today that the intended use for its Food and Drug Administration (FDA) Emergency Use Authorization (EUA) SARS-CoV-2 RNA STAR Comple...

1 month ago - PRNewsWire

LumiraDx Reports Third Quarter 2021 Financial Results

LONDON, Nov. 10, 2021 /PRNewswire/ -- LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for the quarter ended September 30, 2021. Reven...

2 months ago - PRNewsWire

LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10

LONDON, Nov. 2, 2021 /PRNewswire/ -- LumiraDx  (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter 2021 financial results on Wednesday, ...

2 months ago - PRNewsWire

LumiraDx Announces the Intended Use for its FDA EUA Authorized High Sensitivity COVID-19 Antigen Test has been Expand...

LONDON, Nov. 1, 2021 /PRNewswire/ -- Today, LumiraDx (Nasdaq: LMDX) a next-generation point of care (POC) diagnostics company announced that the intended use for its Food and Drug Administration (FDA) E...

2 months ago - PRNewsWire

Why Are LumiraDx Shares Trading Higher Today?

LumiraDx (NASDAQ:LMDX) has received emergency use approval by India's Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test.  The test detects antigen nucleocapsid protein from a n...

3 months ago - Benzinga

Here is how LumiraDx is making COVID-19 testing easier

LumiraDx (NASDAQ: LMDX) has received emergency user approval for the SARS-CoV-2 Antigen test in India from the Central Drugs Standard Organisation. The diagnostic Antigen test is designed to detect anti...

3 months ago - Invezz

LumiraDx receives approval for its COVID-19 Antigen Test for use in India

LONDON, Oct. 20, 2021 /PRNewswire/ -- Today, LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics testing company announced it has received emergency use approval by India's Central Drug...

3 months ago - PRNewsWire

LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test

LONDON, Oct. 15, 2021 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostic company, today announced it has submitted the LumiraDx SARS-CoV-2 & Flu A/B Test to the Food and...

3 months ago - PRNewsWire

CA Healthcare Acquisition Corp. and LumiraDx Limited Announce Effectiveness of Registration Statement and September 2...

BOSTON--(BUSINESS WIRE)--CA Healthcare and LumiraDx Announce Effectiveness of Registration Statement and September 28, 2021 Special Meeting to Approve Business Combination

4 months ago - Business Wire

LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation ...

BOSTON & LONDON--(BUSINESS WIRE)--LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation Point-of-Care Diagnostics

5 months ago - Business Wire

INVESTIGATION ALERT: Halper Sadeh LLP Investigates MCAD, CAHC, ROT, MUDS, LATN; Shareholders are Encouraged to Contac...

NEW YORK, April 29, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Mountain Crest Acquisition Corp. II (NASDAQ: MCAD)  c...

Other symbols:MUDS
8 months ago - PRNewsWire

Covid Testing Company LumiraDx Goes Public in SPAC

Apr.07 -- LumiraDx Ltd., a diagnostic company that produces Covid-19 tests, is going public through a reverse merger with a blank-check company.

9 months ago - Bloomberg Markets and Finance

Diagnostics company LumiraDX to go public via merger with SPAC in deal valued at about $5 billion

LumiraDX Ltd., a point of care diagnostics testing company, is going public via a merger with special purpose acquisition corporation, or SPAC, CA Healthcare Acquisition Corp. , in a deal with a pro for...

9 months ago - Market Watch

LumiraDx, a Next-Generation Point of Care Diagnostics Testing Company to List on Nasdaq via Merger with CA Healthcare...

BOSTON & LONDON--(BUSINESS WIRE)--LumiraDx, a Next-Generation Point of Care Diagnostics Testing Company to List on Nasdaq via Merger with CA Healthcare Acquisition Corp

9 months ago - Business Wire